We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins
News

Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins

Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins
News

Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Merck Serono, a division of Merck KGaA, announced has that it has entered into a collaboration with Flamel Technologies to investigate the applicability of Flamel's Medusa® technology for the extended release of a therapeutic protein of Merck Serono's portfolio.

Under the terms of the agreement, Merck Serono will make an upfront payment of EUR 2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund R&D efforts to be performed at Flamel. Financial terms of a license agreement up through potential commercialization of this formulation have been agreed between the parties.

"We are delighted to enter into this partnership with Flamel, as it gives Merck Serono access to a technology that may further improve the therapeutic potential of compounds in our portfolio", said Bernhard Kirschbaum, Merck Serono's Head of Research.

"As Flamel's Medusa® technology allows for longer intervals between administrations of injectable proteins compared to standard formulations, we hope to offer an improved convenience for patients requiring treatment by injection. As a consequence, we anticipate that employing this technology will lead to better treatment outcomes for patients."

Stephen H. Willard, Flamel's Chief Executive Officer, stated, "We are pleased to have reached an agreement with Merck Serono. The Medusa® platform is a best-in-class technology for the controlled delivery of proteins, peptides, and other molecules. This applicability to a wide range of molecules is a key strength of the platform, as is the ability to sustain release without affecting bioactivity. Merck Serono is the ideal partner for this project and we look forward to working together on such an exciting opportunity."

Advertisement